Cipla launches ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India

10 May 2022 Evaluate

Cipla has launched ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me. With this, the company is expanding its diagnostics offering to bring more advance and innovative products. The company will be responsible for the distribution of RT Direct kits in India and has commenced supply of the same.

This kit is validated at the Indian Council of Medical Research (ICMR) approved Centre. It is based on the ‘gold standard RT-PCR method with coverage of three target genes specific to SARS-COV-2 along with IC, which is much advanced than others having 1 or 2 target genes. This greatly increases the sensitivity of the RTPCR test.

RT-Direct test protocol does not require any RNA extraction process, making it faster and helps deliver results in just 45 minutes. It will also increase the throughput of any testing lab by threefold compared to the normal RT-PCR test protocol time of 120-150 minutes.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1491.40 -3.00 (-0.20%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×